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Neuropsychological and functional outcomes in recent-onset
major depression, bipolar disorder and schizophrenia-spectrum
disorders: a longitudinal cohort study
RSC Lee1, DF Hermens1, SL Naismith1, J Lagopoulos1, A Jones1, J Scott2,3, KM Chitty1, D White1, R Robillard1, EM Scott1,4 and IB Hickie1
Functional disability is the lead contributor to burden of mental illness. Cognitive deﬁcits frequently limit functional recovery,
although whether changes in cognition and disability are longitudinally associated in recent-onset individuals remains unclear.
Using a prospective, cohort design, 311 patients were recruited and assessed at baseline. One hundred and sixty-seven patients
met eligibility criteria (M= 21.5 years old, s.d. = 4.8) and returned for follow-up (M= 20.6 months later, s.d. = 7.8). Two-hundred and
thirty participants were included in the ﬁnal analysis, comprising clinically stable patients with major depression (n= 71), bipolar
disorder (BD; n= 61), schizophrenia-spectrum disorders (n= 35) and 63 healthy controls. Neuropsychological functioning and self-
rated functional disability were examined using mixed-design, repeated-measures analysis, across diagnoses and cognitive clusters,
covarying for relevant confounds. Clinical, neuropsychological and functional changes did not differ between diagnoses (all
P40.05). Three reliable neuropsychological subgroups emerged through cluster analysis, characterized by psychomotor slowing,
improved sustained attention, and improved verbal memory. Controlling for diagnosis and changes in residual symptoms, clusters
with improved neuropsychological functioning observed greater reductions in functional disability than the psychomotor slowing
cluster, which instead demonstrated a worsening in disability (Po0.01). Improved sustained attention was independently
associated with greater likelihood of follow-up employment (Po0.01). Diagnosis of BD uniquely predicted both follow-up
employment and independent living. Neuropsychological course appears to be independently predictive of subjective and
objective functional outcomes. Importantly, cognitive phenotypes may reﬂect distinct pathophysiologies shared across major
psychiatric conditions, and be ideal targets for personalized early intervention.
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INTRODUCTION
Early characterization and treatment of cognitive deﬁcits in major
psychiatric disorders have the potential to prevent progression to
more severe psychopathology1,2 and functional disability.2–6 This
notion is supported by data showing that those who go on to
develop major depression (MD),7,8 bipolar disorder (BD)9 and
schizophrenia-spectrum disorder (SZ)7,8 have poorer cognitive
functioning in childhood than those who do not. Contrary to this
body of evidence, data from other BD cohorts have identiﬁed
superior cognitive functioning in those who later develop mania
compared with those who remain healthy.8,10 Nevertheless, the
case for a premorbid or neurodevelopmental origin to cognitive
dysfunction in psychiatric disorders is additionally supported by
data showing that more pronounced neuropsychological dysfunc-
tion in established cases confers a greater risk of relapse in
depression11 and psychosis.12 Despite widespread and persisting
cognitive dysfunction in those with psychotic and mood
disorders,13–15 and its effects on poorer prognosis and functional
outcomes,16–18 the majority of studies have focused on well-
established illness rather than recent-onset cases. Prioritizing
research efforts toward recent-onset disorders is motivated by
ﬁndings demonstrating that cognitive deﬁcits in ﬁrst-episode
MD,19 BD20 and SZ21 contribute to functional disability
independently of clinical and diagnostic considerations.22 The
majority of published studies have relied on cross-sectional
designs, whereas longitudinal studies have the unique ability to
determine causative mechanisms, and can obviate between- and
within-study heterogeneity frequently confounding cross-
sectional studies.20
At a group level, it is now widely accepted that cognitive
impairment in SZ remains relatively stable following the ﬁrst
episode of illness,23 at least until older adulthood.24 By contrast,
there remains little consensus regarding the longer-term trajec-
tory of cognitive functioning in mood disorders. The majority of
longitudinal studies in MD have been very short term, with just
two controlled studies conducted over a follow-up period of at
least 1 year. One study found improved verbal memory,25 whereas
another study identiﬁed psychomotor speed and executive
functioning gains.26 Results in BD are also mixed, with studies
ﬁnding improved27,28 and stable cognitive deﬁcits,29,30 and other
studies ﬁnding focal declines.31,32 Thus, the neuropsychological
trajectory in mood disorders appears heterogeneous, and the
mechanisms of change remain unclear. Further, studies have been
limited by using the Global Assessment of Functioning Scale,
conﬂating functional outcome with symptomatology.33 Among
the studies including other measures of functional outcome, none
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collected data at two time points. Importantly, only two long-
itudinal studies have examined recent-onset mood disorders in
young adults.26,28 Targeting early adulthood is critical given that
interventions delivered during this period will likely have a greater
impact on years lived with disability than focusing on later stages
of the lifespan. Examining recent-onset cohorts also affords the
added advantage of being able to circumvent the effects of
prolonged medication use. On the whole, the above literature
suggests that there is considerable heterogeneity in neuropsy-
chological trajectories across MD and BD, and whether this differs
from SZ, particularly in recent-onset cases, remains unknown.
Furthermore, whether these trajectories can predict functional
changes is unclear. Clarifying the time course and functional
impact of cognitive deﬁcits in mood disorders, compared with SZ,
have implications for the understanding of the pathophysiology
that may be shared across mood and psychotic disorders,34,35 and
for the development of novel and personalized early
interventions.36 The identiﬁcation of cognitive subgroups has
already been successfully demonstrated in cross-sectional samples
of MD,37 BD38 and SZ,39 and it remains to be empirically
determined whether this can be extended to longitudinal samples
that cut across traditional diagnostic boundaries. In addition, our
understanding of whether the functional implications of neuro-
psychological dysfunction reﬂect real-world outcomes such as
employment remains limited.
Here we sought to clarify the longitudinal course of neuropsy-
chological functioning in clinically stable adolescents and young
adults recently diagnosed with MD or BD, compared with a
broadly deﬁned SZ cohort at a similarly early stage of illness. We
investigated whether neuropsychological changes and/or stability
are shared across disorders, and potentially masked by traditional
diagnostic classiﬁcations through a data-driven approach using
cluster analysis. Finally, we examined whether neuropsychological
changes are associated with changes in functional disability and,
secondarily, with objective functional outcomes, such as
employment.
MATERIALS AND METHODS
Participants
Participants were consecutively recruited from a specialized youth mental
health clinic at the Brain and Mind Research Institute.22,40 Inclusion criteria
included persons aged 12–35 years presenting with a mood and/or
psychotic syndrome. Healthy control (HC) participants were recruited from
the same metropolitan region with no psychiatric or substance depen-
dence history. HC subjects were recruited to serve as a comparison cohort
from the same catchment area to control for socioeconomic characteristics
that covary with geographic location. Participants were excluded if they
had a neurological condition, current substance dependence (to eliminate
the confound of acute substance use or withdrawal), insufﬁcient English
language skills or intellectual disability. The study was approved by the
University of Sydney Human Research Ethics Committee, and all
participants (or guardians, if participants were o16 years) gave written
informed consent. Data included in the current study were collected
between 9 July 2008 and 10 February 2014.
Procedure
Psychiatrists and research psychologists conducted assessments at base-
line and follow-up. Clinical diagnoses were determined by psychiatrists at
both time points in accordance with Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, Text Revision. Follow-up clinical diagnoses
were formally corroborated through case review by a board-registered
psychologist according to the Structured Clinical Interview For DSM-IV-TR
Axis I Disorders (non-patient edition).41 Any discrepancies were resolved by
consensus between the treating psychiatrist and experienced research
psychologists (see Supplementary Table 1 for diagnostic breakdown). We
acknowledge that some may not consider psychotic disorder not
otherwise speciﬁed to fall under ‘schizophrenia’ as narrowly deﬁned.
However, we classiﬁed psychotic disorder not otherwise speciﬁed into a
more broadly deﬁned ‘schizophrenia-spectrum’ cohort in the current
study, as previously done in the literature.42,43 All patients continued to
receive ‘treatment as usual’ between assessments with no interference to
their prescribed course of treatment.
Measures
Clinical symptoms were rated on the Brief Psychiatric Rating Scale,44 using
empirically derived symptom (min–max) subscores,45 namely, depression
(6–42), mania (7–49), positive symptoms (7–49), negative symptoms (5–35)
and disorientation (2–14). Minimum scores were indicative of nil
symptoms, whereas a single multiplication of the minimum score would
correspond to an increase sequentially from none, very mild, mild,
moderate, moderately severe, severe and ﬁnally to extremely severe (for
example, depression of 18 would equate to ‘mild’ severity).
Neuropsychological measures were chosen on the basis of sound
validity and reliability,46 relevance to the diagnoses under study,19–21
overlap with the instruments used in the Measurement and Treatment
Research to Improve Cognition in Schizophrenia initiative,47–49 and their
degree of co-variation with one another (that is, we avoided highly
correlated measures as this would artiﬁcially skew cluster solutions).
Premorbid intellectual functioning (premorbid IQ) was estimated using the
Wechsler Test of Adult Reading (WTAR)50 or Wide Range Achievement
Test—fourth edition (WRAT-4; for participants o16 years).51 Psychomotor
speed was measured using Trail Making Test—Part A (TMT-A).52 Verbal
learning and memory were indexed using Logical Memory I and Logical
Memory II Percent Retention (LM-I and LM-Ret).53 Sustained attention,
visual learning and memory, and conceptual ﬂexibility were assessed using
Rapid Visual Processing Hits A0 (RVP-A0), Paired Associate Learning-
adjusted errors (PAL) and Intra-/Extradimensional shift test-total errors
(IED), respectively, from the Cambridge Neuropsychological Test Auto-
mated Battery (CANTAB).54 Verbal ﬂuency was examined using the
Controlled Oral Word Association Test (letters F, A and S; FAS).55 All
neuropsychological raw scores were standardized into z-scores (higher
scores denoted better performance) based on normative data50,53,54,56–58
with established reliability and validity.46 This was to control for age-
related changes in cognitive development, given the current age range
coinciding with a critical period of cognitive and brain development.46
Self-ratings of disability and quality of life were obtained using the total
scores from the World Health Organization Disability Assessment Scale
version 2.0 (WHODAS-II)59 and World Health Organization Quality of Life
(WHOQoL-BREF) Scale,60 respectively. A higher WHODAS-II score denoted
greater functional disability, whereas a higher WHOQoL score denoted
better quality of life. For the secondary analyses, objective real-world
outcomes at follow-up were ascertained through interview and ques-
tionnaires probing information relating to employment and/or study, and
relationship- and independent living statuses.
Statistical analyses
Statistical analyses were conducted using SPSS Version 20 (SPSS, Chicago,
IL, USA). One-way analyses of variance and χ2-tests were conducted to
examine baseline differences. Mixed-design, repeated-measures analyses
of covariance were conducted to assess overall change and diagnosis-by-
time interactions in clinical, neuropsychological and functional character-
istics, while controlling for age and gender.
Monte Carlo simulation has previously shown that the best-performing
clustering algorithm was a two-step process involving (a) determining
membership through hierarchical cluster analysis and (b) assigning group
membership through k-means clustering.61 Therefore, a hierarchical cluster
analysis was conducted on neuropsychological change scores to identify
distinct and internally homogeneous change subgroups using Ward’s
method of minimum variance with squared Euclidean distance.37,62 An
optimal cluster solution was determined from the agglomeration schedule
and dendrogram, and k-means clustering was conducted to segregate
patients into clusters. A good cluster solution is one where the data
separates into reliable (that is, stable) and externally valid (that is,
meaningful) groups.63 Accordingly, we examined the stability of clusters
through multiple methods as previously recommended64 by conducting
further k-means clustering on data after (a) case order was randomized,
and (b) a random 50% subsample was generated. Cluster membership was
deemed stable when a high percentage of cases were reassigned to the
same clusters.
Baseline demographic and clinical characteristics between clusters were
examined using analyses of variance and χ2-tests. Mixed-design repeated-
measures analyses of covariance were used to examine overall changes
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and cluster-by-time interactions in clinical symptoms, covarying for age,
gender and diagnosis. This analysis was repeated for neuropsychological
functioning, functional disability and quality of life, while additionally
covarying for differential changes in symptoms between clusters.
Secondarily, we examined whether the functional relevance of neuropsy-
chological trajectories would extend to objective real-world
outcomes through logistic regression, controlling for the same covariates.
Speciﬁcally, we examined whether clusters would be predictive of (1)
employment in those who were not in full-time education, (2) relationship
status and (3) independent living in adults (that is, having moved out of
the family home). We included only those who were not in full-time
education in our ﬁrst analysis, as we could not reasonably deﬁne
participants who were in full-time education, but not employed, as
occupationally disengaged in the same way as individuals who were both
not in full-time education and not employed. Further, we hypothesized
that living independently away from the family home would likely rely on
an independent source of remuneration. As such, we added employment
as a covariate of independent living status. Signiﬁcance was set at 0.05
(two-sided). All contrasts were Bonferroni-adjusted to control for type I
error rate.
RESULTS
Baseline characteristics by diagnosis
At baseline, 311 patients were recruited and assessed, with 197
participants successfully returning for follow-up (Supplementary
Figure 1). Those who were lost to follow-up did not differ on age,
sex, educational attainment, symptomatology, functional disability
or quality of life, although they had lower premorbid IQ (100.65 vs
104.45, F = 9.31, Po0.01), poorer verbal learning (LM-I, F = 6.93,
Po0.01) and worse conceptual ﬂexibility (IED, F = 4.84, Po0.05).
No other neuropsychological variables differed between those
who returned and those who did not.
Of those who returned for follow-up, 30 patients were deemed
ineligible and were excluded from the ﬁnal analysis
(Supplementary Figure 1 for reasons of exclusion). This left a
sample of 167 patients who were case-reviewed and consensus-
rated for a formal diagnosis. The ﬁnal sample of 167 patients
comprised 71 MD, 61 BD and 35 SZ cases. An HC sample was also
recruited and assessed at baseline (n= 63). All patients were
reassessed, on average, 20.6 months later (s.d. = 7.8, range = 6–
48 months). Most participants were reassessed between 12 and
36 months after the baseline assessment (n= 157), with only 3%
(n= 5) falling below and above this threshold. Importantly, there
were no signiﬁcant differences in follow-up period between
diagnoses.
Mean age of participants differed between groups (F = 12.8,
Po0.001; Table 1), with MD participants being younger than BD
(Po0.01), SZ (Po0.05) and HC cases (Po0.001). Distribution of
sex differed between groups (χ2 = 17.7, Po0.001), with SZ having
a higher proportion of males than the other three groups (all
Po0.05). Average years of education differed between groups
(F = 13.0, Po0.001), with HC participants being more educated
than the other three groups (all Po0.01). Average premorbid IQ
(s.d.) was 104.6 (9.4), with no signiﬁcant differences between
groups.
Table 1. Sample characteristics at baseline by diagnosis
Measures MD (n= 71) BD (n= 61) SZ (n=35) HC (n= 63) Inferential statistics
Mean s.d. Mean s.d. Mean s.d. Mean s.d. F P-value Contrasts
Demographic
Age 19.9 4.2 22.8 5.1 22.7 4.5 24.1 3.7 12.8a o0.00 MDoBD, SZ, HCb
Education (years) 12.1 2.4 12.9 2.6 12.5 2.6 14.5 2.0 13.0 o0.00 MD, BD, SZoHCb
Premorbid IQ 104.8 10.8 104.6 8.8 103.5 10.6 105.0 7.7 0.2 NS
Clinical
Age at presentation 19.0 3.9 21.7 4.8 21.9 4.6 7.9 o0.00 MDoBD, SZb
BPRS depression 15.1 5.0 13.5 5.2 13.1 6.1 2.1 NS
BPRS mania 9.8 4.0 10.6 4.4 10.3 4.9 0.6 NS
BPRS positive 10.8 3.3 10.4 3.4 13.1 5.3 3.7a 0.03 MD, BDoSZb
BPRS negative 9.8 4.0 10.6 4.4 10.3 4.9 3.1a NS
BPRS disorientation 2.2 0.5 2.2 0.5 2.6 1.1 2.0a NS
Functional
WHODAS-II total 41.6 14.5 36.2 18.9 39.5 16.5 1.5 NS
WHOQoL total 46.8 10.7 48.8 10.9 47.5 10.4 0.5 NS
Follow-up interval (months) 20.7 7.7 19.9 7.6 21.8 8.2 0.7 NS
N % N % N % N % χ2 P-value
Demographic
Gender (female) 45 63.4 41 67.2 9 25.7 35 55.6 17.7 o0.00 MD, BD, HC4SZb
Clinical
Psychotic features 12 16.9 16 26.2 35 100.0 82.0c o0.00 MD, BDoSZb
Medications
Any psychotropic 44 62.0 51 83.6 31 88.6 11.9 o0.00 MDoBD, SZb
Antidepressant 37 52.1 30 49.2 12 34.3 3.1 NS
Antipsychotic 19 26.8 34 55.7 27 77.1 26.2 o0.00 MD, BDoSZb
Lithium or anticonvulsant 4 5.6 24 39.3 6 17.1 23.4c o0.00 MD, SZoBDb
Abbreviations: BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale; HC, healthy control; MD, major depression; NS, nonsigniﬁcant; SZ, schizophrenia-
spectrum disorder; WHODAS-II, World Health Organization Disability Assessment Schedule Version 2.0; WHOQoL, World Health Organization Quality of Life
(BREF) Scale. aWelch’s statistic correction for violation of homoscedasticity. bBonferroni-adjusted contrasts between individual diagnostic groups statistically
signiﬁcant (Po0.05). cFisher’s exact test correction for cells with no5.
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Age of clinical presentation differed signiﬁcantly between
diagnostic groups (F = 7.9, Po0.01), with MD participants
presenting at an earlier age than BD and SZ groups (all
Po0.01). The length of time between presentation and baseline
assessment did not differ between diagnostic groups. Qualita-
tively, mean symptom scores all fell in the very mild-to-mild range
across diagnoses, corroborating the clinically stable status of our
cohort. Groups differed in residual positive symptoms at baseline
(F = 7.9, Po0.05), with SZ having more severe symptoms than MD
(Po0.05) and BD (Po0.01). This is consistent with differences in
history of psychotic features between groups (χ2 = 82.0, Po0.001),
with a higher proportion of psychotic presentations in the SZ
group than the MD or BD groups (all Po0.05). Antipsychotic use
(χ2 = 26.2, Po0.001) and mood stabilizer use (lithium/anticonvul-
sant; χ2 = 23.4, Po0.001) were different between groups, with
these being more common in SZ and BD groups (all Po0.05),
respectively.
Cognitively, diagnostic groups differed on all measures at
baseline except FAS (all Po0.05; Figure 1 and Supplementary
Table 2). The SZ participants were most impaired, performing
worse than HC on all measures except FAS (Po0.05), whereas MD
and BD participants performed at an intermediate level between
HC and SZ.
There were no baseline differences in self-rated functional
disability (WHODAS-II) or quality of life (WHOQoL) between
diagnostic groups (all P40.05).
Clinical, neuropsychological and functional changes by diagnosis
There were no overall changes or diagnosis-by-time interactions in
symptoms. Cognitively, overall improvements were only found for
LM-Ret (F = 4.9, Po0.05). To assess for the inﬂuence of practice
effects, follow-up interval was correlated with LM-Ret change, as
more pronounced improvements would theoretically be asso-
ciated with shorter follow-up intervals if practice effects were at
play. However, this was nonsigniﬁcant (r=− 0.062, P= 0.434) and
argues against the presence of practice effects. All diagnosis-by-
time interactions for cognitive functioning were nonsigniﬁcant.
Functionally, there were no signiﬁcant overall changes in
WHODAS-II, WHOQoL or diagnosis-by-time interactions (Figure 2).
Cluster analysis of neuropsychological change
Hierarchical clustering identiﬁed three distinct clusters
(Supplementary Figure 2 and Supplementary Table 2), showing
predominant reductions in psychomotor speed (PsySpd− , n= 36),
improvement in sustained attention (SusAtn+, n= 70) and
improvement in verbal memory (VerMem+, n= 56). Two random-
ized data sets generated largely similar clusters with 93.8 and
87.7% of all cases being assigned to the same clusters. Moreover, a
randomly generated subsample of half of participants produced
similar clusters, with 80.0% of participants being assigned to the
same clusters and the most pronounced changes found on the
same neuropsychological measures (TMT-A, RVP-A and LM-Ret).
Demographic and clinical characteristics of clusters
At baseline (Table 2), clusters did not signiﬁcantly differ on age,
sex, premorbid IQ, educational attainment, clinical symptoms,
medication use or length of time between presentation and
baseline assessment. Notably, follow-up interval or diagnosis did
not differ between clusters (Supplementary Table 3).
There were no overall changes in symptoms. However, when
examining differential changes at follow-up (Supplementary
Figure 3), discrepancies between clusters emerged for both
positive (F = 4.2, Po0.05) and negative symptoms (F = 4.1,
Po0.05). Speciﬁcally, the VerMem+ cluster showed improve-
ments in positive and negative symptoms, whereas the PsySpd−
cluster showed worsening of negative symptoms, while their
positive symptoms remained stable. The differential changes in
symptoms between these two clusters were statistically signiﬁcant
(Po0.01). The rate of change in the SusAtn+ cluster for both
positive and negative symptoms did not differ from any of the
other two clusters.
Functional disability by clusters
Baseline functional disability differed between clusters (F = 4.0,
Po0.05), with the PsySpd− cluster reporting a lower level of
disability at baseline compared with the VerMem+ cluster
(Po0.05). Given clusters did not differ on any demographic or
clinical factors, we conducted additional post hoc analyses on
baseline neuropsychological scores to clarify the nature of the
baseline difference in functional disability. Accordingly, the
PsySpd− cluster was more impaired than the VerMem+ cluster
on all three learning and memory measures (PAL, LM-I and LM-Ret,
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Figure 1. Mean standardized neuropsychological performance
(± s.e.) at baseline (a) and mean standardized neuropsychological
change (± s.e.) at follow-up (b) by diagnosis. At baseline (a),
neuropsychological functioning was signiﬁcantly different between
diagnoses across all measures (except FAS). Speciﬁcally, patients
with schizophrenia-spectrum disorder (SZ) performed worse than
healthy controls (HCs; Po0.05) on all measures (except FAS). Major
depression (MD) and bipolar disorder (BD) each performed worse
than HC (Po0.05) on RVP-A, PAL and LM-Ret. Separately, MD and BD
performed worse than HC (Po0.05) on TMT-A and LM-I, respec-
tively. MD and BD each outperformed SZ on TMT-A, PAL, LM-I, LM-
Ret and IED (Po0.05). MD and BD did not differ from each other on
any measure (P40.05). At follow-up (b), LM-Ret was the only
measure improving signiﬁcantly over time across diagnoses
(Po0.05). All group × time interactions were nonsigniﬁcant
(P40.05). FAS, Controlled Oral Word Association Test; IED, Intra-/
Extradimensional shift test-total errors; LM-I, Logical Memory I; LM-
Ret, Logical Memory II Percent Retention; PAL, Paired Associates
Learning-adjusted errors; RVP-A, Rapid Visual Processing Hits A0;
TMT-A0, Trail Making Test—Part A.
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Po0.01). No other cognitive functions differed between these
two clusters.
At follow-up, WHODAS-II change differed between clusters
(F = 5.6, Po0.01; Figure 2). Speciﬁcally, SusAtn+ and VerMem+
clusters were each changing at different rates compared with the
PsySpd− cluster (Po0.01), such that improved sustained atten-
tion and improved verbal memory were associated with reduced
functional disability, whereas psychomotor slowing was linked to
a worsening of functional disability. Clinical symptom changes did
not signiﬁcantly predict WHODAS-II change over and above
cluster membership (P40.05). By comparison, WHOQoL changes
did not differ between clusters (P40.05).
Secondary analyses of real-world outcomes at follow-up
Of those not currently in full-time education, those in the SusAtn+
cluster were more likely to be employed at follow-up than those in
the PsySpd− cluster (odds ratio (OR) = 7.3, 95% conﬁdence
interval (CI), 2.0–26.8, Po0.005; Table 3), with improved sustained
attention contributing an additional 9.2% to the variance in
follow-up employment (ΔR2 = 0.092, Po0.01). Cluster member-
ship did not independently predict the likelihood of being in a
relationship or living independently from family members
(P40.05). By comparison, being female was a signiﬁcant predictor
of being in a relationship at follow-up (OR= 3.12, 95% CI, 1.4–6.9,
Po0.01). Of note, although diagnosis did not differentiate
between changes in functional disability or quality of life, being
diagnosed with BD increased the likelihood of follow-up employ-
ment (OR= 5.37, 95% CI, 1.6–18.5, Po0.01) and independent
living (OR= 3.39, 95% CI, 1.0–11.1, Po0.05) than being diagnosed
with SZ.
DISCUSSION
At a group level, the early course of neuropsychological
functioning in MD and BD is generally comparable to a broadly
deﬁned cohort of SZ, whereby functioning remains largely stable.
This stability is generally consistent with ﬁndings within the ﬁrst-
episode psychosis literature.65 Verbal memory was the only
current exception, which improved at follow-up across diagnoses,
and corroborates data in recent-onset MD26 and BD.28 Interest-
ingly, prior investigations examining the association between
clinical and neuropsychological change in MD have consistently
found that changes in depression are correlated with changes in
verbal memory,66 in keeping with meta-analytic evidence
supporting the same association in cross-sectional studies of
ﬁrst-episode MD.19 Given that residual depressive symptoms did
not signiﬁcantly change in the current study, any potential
relationship between reductions in depression and improvement
in verbal memory may have been obscured by a restriction in
range and warrants further examination in future studies.
An alternative approach to interrogate the longitudinal course
of neuropsychological functioning was to use a data-driven cluster
analysis to help identify potential discrete cognitive pathways
obscured by simple diagnostic aggregation.67 Three distinct and
reliable neuropsychological subgroups emerged, representing
predominantly psychomotor slowing and improvements in
sustained attention and verbal memory. Diagnostic makeup did
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d
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Figure 2. Mean baseline and follow-up WHODAS-II (a, b) and WHOQoL (c, d) scores (± s.e.). aOverall change and group× time interaction is
nonsigniﬁcant (P40.05). bOverall change is nonsigniﬁcant (P40.05), whereas group × time interaction is signiﬁcant (Po0.01). Pairwise
comparisons showed that the SusAtn+ and VerMem+ clusters were each changing at signiﬁcantly different rates from the PsySpd− cluster
(Po0.01 and Po0.001, respectively). No other pairwise comparison was signiﬁcant. cOverall change and group × time interaction is
nonsigniﬁcant (P40.05). dOverall change and group × time interaction is nonsigniﬁcant (P40.05). WHODAS-II, World Health Organization
Disability Assessment Schedule Version 2.0; WHOQoL, World Health Organization Quality of Life (BREF) Scale.
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not differ between clusters, underscoring the notion that the
course of neuropsychological functioning does not appear to be
diagnosis speciﬁc. Further analyses revealed that changes in
positive and negative symptoms differed between clusters, with
improved verbal memory associated with reductions in residual
positive and negative symptoms, whereas psychomotor slowing
was linked to a worsening of negative symptoms. This ﬁnding
converges with meta-analytic data in ﬁrst-episode psychosis,
showing an inﬂuence of both positive and negative symptom
changes on the severity of cognitive dysfunction.65
Importantly, the external validity of the neuropsychological
clusters was further supported by their associations with
functional changes. Speciﬁcally, improved verbal memory and
sustained attention were each coupled with greater reductions in
self-rated functional disability than psychomotor slowing, over
and above the effects of diagnosis and symptom alleviation.
Surprisingly, another study investigating the association between
cognitive and functional changes also found that improved verbal
memory and sustained attention were correlated with reduced
functional impairments, albeit in older cases with longstanding
BD.27 The current ﬁndings show that this relationship also holds
for the full spectrum of major mood and psychotic illnesses, even
at the early stages of illness. Moreover, it highlights the
incremental value of neuropsychology over and above diagnostic
considerations in predicting the course of functional changes. It is
interesting to note that the psychomotor slowing cluster
presented with less functional disability than the improved verbal
memory cluster at baseline. Our post hoc analyses revealed that
this difference appeared to be related to learning and memory
being more superior in the psychomotor slowing cluster and
converges with evidence showing that episodic memory seems to
be most strongly linked to psychosocial functioning compared
with other neuropsychological functions.6
Contrary to functional disability, changes in quality of life in
recent-onset MD, BD and SZ do not appear to be correlated with
neuropsychological changes. Instead, the clusters with improved
quality of life were associated with reductions in positive and
negative symptomatology, consistent with the ﬁrst-episode
psychosis literature showing that quality of life appears to be
more strongly related to psychopathology than neuropsychologi-
cal functions.68 This distinction highlights the importance of
examining clinical phenotypes separately from diagnostic entities,
as certain symptom dimensions are evidently critical to functional
outcomes, such as quality of life, irrespective of diagnosis.
Secondarily, individuals who were not in full-time education,
but whose sustained attention and self-rated functional disability
improved, were more likely to be employed at follow-up than
those whose experienced psychomotor slowing and functional
decline. Few previous longitudinal studies had speciﬁcally
examined real-world functional outcomes,22 and this ﬁnding
lends preliminary support to the ecological validity of self-rated
functional disability in the domain of occupational functioning. By
Table 2. Sample characteristics at baseline by cluster
Measures PsySpd−
(n= 36)
SusAtn+ (n= 70) VerMem+
(n=56)
Inferential statistics
Mean s.d. Mean s.d. Mean s.d. F P-value Contrasts
Demographic
Age 22.1 6.0 21.6 4.5 20.8 4.4 0.9a NS
Education (years) 12.4 2.8 12.7 2.3 12.0 2.5 1.0 NS
Premorbid IQ 106.6 10.4 104.0 8.4 103.3 11.3 1.3 NS
Clinical
Age at presentation 20.6 4.8 21.0 4.6 19.9 4.4 0.8 NS
BPRS depression 13.8 5.5 13.9 5.4 14.6 5.2 0.4 NS
BPRS mania 10.1 4.3 10.6 5.0 9.9 3.5 0.4 NS
BPRS positive 10.7 3.6 11.0 3.8 11.8 4.4 0.9 NS
BPRS negative 7.1 2.4 7.3 2.9 7.7 3.2 0.5 NS
BPRS disorientation 2.1 0.5 2.3 0.7 2.3 0.9 0.7 NS
Functional
WHODAS-II total 33.2 18.6 38.3 15.0 44.0 16.9 4.0 0.02 PsySpd− oVerMem+b
WHOQoL total 48.3 11.9 49.0 10.3 45.3 10.1 1.9 NS
Follow-up interval (months) 20.3 5.6 20.8 7.5 20.8 9.1 0.1 NS
N % N % N % χ2 P-value
Demographic
Gender (female) 23 63.9 41 58.6 30 53.6 1.0 NS
Clinical
Psychotic features 14 38.9 23 32.9 23 41.1 1.0 NS
Medications
Any psychotropic 27 75.0 52 74.3 42 75.0 0.0 NS
Antidepressant 18 44.4 32 45.7 28 50.0 0.3 NS
Antipsychotic 21 58.3 28 40.0 28 50.0 3.4 NS
Lithium or anticonvulsant 8 22.2 11 15.7 13 23.2 1.3 NS
Abbreviations: BPRS, Brief Psychiatric Rating Scale; NS, nonsigniﬁcant; PsySpd− , psychomotor speed decline; SusAtn+, sustained attention improvement;
VerMem+, verbal memory improvement; WHODAS-II, World Health Organization Disability Assessment Schedule Version 2.0; WHOQoL, World Health
Organization Quality of Life (BREF) Scale. aWelch’s statistic correction for violation of homoscedasticity. bBonferroni-adjusted contrasts between individual
clusters statistically signiﬁcant (Po0.05).
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comparison, a diagnosis of BD also increased the likelihood of
follow-up employment, as well as the odds of living indepen-
dently from family members, compared with having a diagnosis of
a SZ. Accordingly, despite diagnosis contributing negligibly to the
course of self-rated functional disability, it appears to have speciﬁc
utility in predicting real-world role, as well as independent living,
outcomes. This is consistent with a burgeoning view within the
literature that there appears to be a subset of BD cases with
undetectable premorbid decline in cognitive functioning.69,70
Instead, at least in the early stages of illness, BD cases may
present with psychosocial functions superior to healthy compar-
ison subjects, which may have accounted for the more favorable
employment and independent living outcomes of BD cases in the
current sample.38,71
Conceptually, the current ﬁnding that diagnostic classiﬁcation
as broadly deﬁned is unable to discriminate the longitudinal
course of clinical symptoms, neuropsychological functioning or
self-rated functional disability has important implications for
psychiatric nosology. It contributes to an emerging view within
psychiatry of a need to refocus efforts toward less arbitrarily
deﬁned and more biologically valid phenotypes under the
Research Domain Criteria framework.72 Solely diagnostic
approaches to study designs continue to obstruct efforts to clarify
the underlying structure of mental illness, as these involve
classifying individuals on various potentially unrelated illness
characteristics likely to have separate underlying
pathophysiologies.73 By comparison, ‘dimensional psychiatry’
using cognitive phenotypes, as exercised in the current study, is
Table 3. Binary logistic regression models predicting follow-up employment, relationship status and independent living
Employment Step 1* (Cox–Snell, R2 = 0.13) Step 2** (Cox–Snell, R2 = 0.22; R2 change**)
B (SE) OR 95% CI P-value B (SE) OR 95% CI P-value
Age 0.01 (0.05) 1.01 0.92–1.11 NS 0.04 (0.05) 1.04 0.93–1.16 NS
Sex (female) 0.22 (0.47) 1.24 0.49–3.14 NS 0.38 (0.53) 1.46 0.52–4.12 NS
Diagnosis
MD 0.35 (0.62) 1.42 0.42–4.83 NS 0.68 (0.65) 1.97 0.55–7.11 NS
BD 1.68 (0.63) 5.37 1.55–18.54 0.008 2.04 (0.68) 7.67 2.03–28.93 0.003
Positive symptom change −0.04 (0.06) 0.96 0.86–1.07 NS − 0.01 (0.06) 0.99 0.88–1.11 NS
Negative symptom change 0.02 (0.07) 1.02 0.88–1.17 NS 0.06 (0.08) 1.07 0.91–1.25 NS
Cluster
SusAtn+ 1.99 (0.66) 7.34 2.01–26.83 0.003
VerMem+ 1.08 (0.71) 2.94 0.73–11.80 NS
Relationship status Step 1** (Cox–Snell, R2 = 0.12) Step 2** (Cox–Snell, R2 = 0.13; R2 change†)
B (SE) OR 95% CI P-value B (SE) OR 95% CI P-value
Age 0.08 (0.04) 1.08 1.00–1.17 NS 0.08 (0.04) 1.09 1.00–1.18 0.041
Sex (female) 1.14 (0.40) 3.12 1.41–6.87 0.005 1.18 (0.41) 3.27 1.47 -7.28 0.004
Diagnosis
MD 0.53 (0.57) 1.70 0.55–5.20 NS 0.61 (0.58) 1.84 0.60–5.68 NS
BD 0.90 (0.56) 2.46 0.82–7.40 NS 0.95 (0.57) 2.57 0.85–7.80 NS
Positive symptom change − 0.02 (0.05) 0.98 0.89–1.08 NS − 0.01 (0.05) 0.99 0.90–1.09 NS
Negative symptom change 0.10 (0.07) 1.11 0.97–1.26 NS 0.12 (0.07) 1.12 0.98–1.29 NS
Cluster
SusAtn+ 0.63 (0.49) 1.88 0.72–4.89 NS
VerMem+ 0.52 (0.53) 1.67 0.59–4.73 NS
Independent living Step 1*** (Cox–Snell, R2 = 0.20) Step 2** (Cox–Snell, R2 = 0.21; R2 change†)
B (SE) OR 95% CI P-value B (SE) OR 95% CI P-value
Age 0.19 (0.06) 1.21 1.09–1.35 0.000 0.19 (0.06) 1.21 1.08–1.35 0.001
Sex (female) 0.06 (0.43) 0.88 0.46–2.48 NS 0.04 (0.44) 1.04 0.44–2.44 NS
Diagnosis
MD 0.95 (0.61) 2.59 0.79–8.54 NS 0.94 (0.62) 2.56 0.77–8.57 NS
BD 1.22 (0.60) 3.39 1.04–11.05 0.043 1.20 (0.61) 3.33 1.01–10.95 0.047
Positive symptom change − 0.07 (0.06) 0.94 0.84–1.05 NS − 0.08 (0.06) 0.93 0.83–1.04 NS
Negative symptom change − 0.02 (0.08) 0.98 0.84–1.15 NS − 0.03 (0.08) 0.97 0.83–1.14 NS
Employment 0.87 (0.42) 2.38 1.05–5.41 0.038 0.91 (0.43) 2.49 1.07–5.79 0.034
Cluster
SusAtn+ − 0.14 (0.57) 0.87 0.28–2.65 NS
VerMem+ −0.46 (0.61) 0.63 0.19–2.08 NS
Abbreviations: BD, bipolar disorder; MD, major depression; NS, nonsigniﬁcant; SusAtn+, sustained attention improvement; VerMem+, verbal memory
improvement. SZ was the reference group for diagnosis, and PsySpd− was the reference group for cluster. *Po0.05, **Po0.01, ***Po0.001, †Nonsigniﬁcant.
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better equipped to isolate independent and internally consistent
subgroups across diagnostic boundaries to better elucidate how
these contribute to disease characteristics and progression.67,74
The current study was limited by the absence of follow-up
assessments for HCs. As such, we could not deﬁnitively rule out
the effects of practice on repeated cognitive testing, although we
did attempt to address this through post hoc analyses showing
that potential cognitive changes secondary to practice were not
supported by the data. Further, the length of follow-up in the
present study was longer than the period conventionally expected
to give rise to sizeable practice effects.46 Despite the length of
follow-up being longer than previously conducted in MD studies,
however, this duration was still shorter than most studies in BD,
and greater lengths of follow-up would be needed to determine
the longer-term changes associated with relapse and disease
progression. The range of follow-up periods in the current study
was also large, and should be more tightly restricted in future
studies, although its effects on the current ﬁndings are likely to be
small, if at all present, given that the length of follow-up was
comparable across all diagnoses and clusters. Further, conducting
neuropsychological follow-up over at least three time points
would be necessary to establish the long-term trajectory of
neuropsychological change or stability. Future studies may also
consider examining whether certain neuropsychological tests are
better at characterizing particular cognitive subgroups, whether
multiple signiﬁcant cognitive impairments would be associated
with worse functional impairments, and whether more severe
symptoms are associated with more multiple cognitive deﬁcits. In
addition, although neuropsychological clusters did not differ on
medication usage, future studies would also beneﬁt from more
treatment-homogeneous samples to rule out the potential effects
of psychotropic medications, or other treatment parameters, on
the longitudinal trajectory of neuropsychological functioning.
Finally, the loss of participants to follow-up was quite substantial
in the current study, and it would be important to replicate the
present ﬁndings in future, larger, multisite cohorts.
To our knowledge, this is the ﬁrst prospective, longitudinal
study to examine neuropsychological functioning across all three
major psychiatric disorders, and is also one of the most statistically
powered. In the medium term, neuropsychological functioning in
recent-onset mood disorders does not appear to differ from that
of schizophrenia-spectrum psychoses. Importantly, the current
data suggest that interrogations based on traditional diagnostic
groups are unlikely to yield insights into the cognitive architecture
of major mood and psychotic disorders, as neuropsychological
changes are shared across, and obscured by, diagnostic bound-
aries. By comparison, deﬁning cases according to cognitive factors
appear to yield more internally consistent subgroups. Neuropsy-
chological changes appear to be related to residual changes in
positive and negative symptoms, suggesting that therapies
targeting these speciﬁc clinical phenotypes may be useful in
preventing or slowing down cognitive deterioration in a subset of
patients with major mood or psychotic illness. Importantly,
cognitive subgroups are functionally relevant and distinct from
clinical state, whereby improvements in cognitive functioning are
independently associated with reductions in self-rated functional
disability. Therefore, cognitive factors may be ideal targets for
novel and personalized early interventions. Further, neuropsycho-
logical clusters have real-world relevance in terms of employment
outcomes. Using data-driven approaches to examine shared
cognitive phenotypes, thus, have the potential to reveal new
insights into the pathophysiological changes that are common
across recent-onset mood and schizophrenia-spectrum illnesses,
and warrants more detailed multimodal genetic, metabolic and
neurobiological investigations.
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